Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)
China · Delayed Price · Currency is CNY 11.52
-0.13 (-1.12%)
Apr 28, 2026, 3:00 PM CST
SHA:600267 Revenue
Zhejiang Hisun Pharmaceutical had revenue of 2.39B CNY in the quarter ending March 31, 2026, a decrease of -9.17%. This brings the company's revenue in the last twelve months to 10.31B, up 6.36% year-over-year. In the year 2025, Zhejiang Hisun Pharmaceutical had annual revenue of 10.55B with 2.03% growth.
Revenue (ttm)
10.31B
Revenue Growth
+6.36%
P/S Ratio
1.30
Revenue / Employee
1.18M
Employees
7,994
Market Cap
13.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.55B | 209.39M | 2.03% |
| Dec 31, 2024 | 10.34B | -32.82M | -0.32% |
| Dec 31, 2023 | 10.37B | -1.66B | -13.82% |
| Dec 31, 2022 | 12.04B | -99.78M | -0.82% |
| Dec 31, 2021 | 12.14B | 782.07M | 6.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Shyndec Pharmaceutical | 9.36B |
| Zhejiang Medicine | 8.82B |
| Guobang Pharma | 6.09B |
| Shenzhen Hepalink Pharmaceutical Group | 5.48B |
| Zhejiang Jiuzhou Pharmaceutical | 5.22B |
| Zhejiang Jingxin Pharmaceutical | 4.00B |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.98B |
| Beijing Aosaikang Pharmaceutical | 1.83B |